

Programme 02/10/2013

World Cord Blood Congress IV and Innovative Therapies for Sickle Cell Disease

Chairs: E. Gluckman (Paris), M. Cavazzana (Paris)

Monaco
October 2013, 24-27

Under the High Patronage of his Serene Highness Prince Albert II of Monaco

Preliminary Programme

Thursday 24th October, 2013

Opening 13.45-14.00

SESSION I: CORD BLOOD STEM CELL

14.00-16.00 Chair: H.E. Broxmeyer (Indianapolis)

14.00-14.30 State of the art including methods for graft facilitation H.E. Broxmeyer (Indianapolis)

Discussants:

14.30-15.00 Cord blood subpopulations and reprogrammed cells G. Koegler (Düsseldorf)

15.00-15.30 Niche regulation of T cell generation D. Scadden (Boston)

15.30-16.00 **Discussion**

16.00-16.30 *Coffee break*

SESSION II: METHODS OF GRAFT FACILITATION

16.30-18.20 Chair: E.J. Shpall (Houston)

16.30-17.00 State of the art E.J. Shpall (Houston)

Discussants:

17.00-17.20 Generation and expansion of human T-lymphoid progenitors from cord blood CD34+ cells in a feeder-cell-free DL-4 culture system I. André-Schmutz (Paris)

17.20-17.40 Building myeloid bridges to enhance engraftment in cord blood transplant and beyond C. Delaney (Seattle)

17.40-18.00 Nicord expanded hematopoietic progenitor cells can outcompete the unmanipulated cord blood unit following myeloablative dual umbilical cord blood transplantation in adults with hematological malignancies J. Kurtzberg (Durham)

18.00-18.20 Hematopoietic stem cell expansion to overcome non-engraftment J. Wagner (Minneapolis)

18.30 **Opening ceremony**

19.30 **Reception: Congress Center**

Friday 25th October, 2013

SESSION III: NEW INNOVATIVE THERAPIES

8.30-12.45 Chair: M. Cavazzana (Paris)

8.30-9.00 Gene therapy for hemoglobinopathies: obstacles, expectancy, availability M. Cavazzana (Paris)

Programme 02/10/2013

Discussants:

9.00-9.20	The present and future challenges of gene therapy for sickle cell disease	F. Mavilio (Evry)
9.20-9.40	Biomarker - based personalized medicine	S. Paczesny (Indianapolis)
9.40-10.00	Engineering cord blood derived T cells to prevent infection after cord blood transplantation	C. Bollard (Washington)
10.00-10.20	Cytokine environment analysis can modify the outcome of hematopoietic stem cell transplantation	F. Touzot (Paris)
10.20-10.40	Tregs for immune modulation	J. Wagner (Minneapolis)
10.40-11.15	<i>Coffee break</i>	
11.15-12.45	Discussion and selected abstract presentations:	
11.15-11.25	Gene expression of hematopoietic stem cells (CD34+) in post-transplant hematopoiesis	F. Frassoni (Genoa)
11.25-11.35	Assesment of HLA diversity in Marseille cord blood bank	C. Chabannon (Marseille)
11.35-11.42	Human cord blood (CB) derived unrestricted somatic stem cells (USSCS) significantly improves survival and wound healing in an animal model of recessive dystrophic epidermolysis bullosa (RDEB)	M. Cairo (New York)
11.42-11.49	Cord blood natural killer (NK) cells as a novel platform for cancer immunotherapy with chimeric antigen receptors (CAR) that incorporate the IL-15 gene	E. Yvon (Houston)
11.49-11.56	Combinations of inhibitory receptors are expressed on cd8 ⁺ t cells in pediatric subjects following bone marrow or umbilical cord blood transplantation	H. Soudeyans (Montreal)
11.56-12.03	Crosstalk between umbilical cord/cord blood endothelial precursors and mesenchymal stromal cells in promoting new blood vessel formation	S. Watt (Oxford)
12.03-12.10	Treatment of mesenchymal stromal cells with immunosuppressive drugs increases their immunoregulatory potency	J. Girdlestone (London)
12.10-12.17	The Italian Cord Blood Platelet Gel project	P. Rebutta (Milan)

12.45-14.00 ***Lunch and poster viewing***

12.45-13.30

SATELLITE WORKSHOP ROOM C

Adam Carr, Zoran Ivanovic, Noel Milpied

- Applying new technology to existing techniques in cord blood processing
Meeting the changing needs of cord blood banking with a cost effective system
- Ex-vivo expansion of cord blood hematopoietic cells for transplantation
- Transplantation of a single allogeneic ex-vivo expanded cord blood unit:
consistent and sustained engraftment in a prospective pilot program

This is a symposium organized and funded by Macopharma

Programme 02/10/2013

SESSION IV: ROLE OF HLA AND OTHER GENETIC MARKERS

14.00-16.30 Chair: E. Petersdorf (Seattle)

14.00-14.30	Overview: State of the art	E. Petersdorf (Seattle)
Discussants:		
14.30-14.50	Role of high resolution HLA typing for cord blood transplantation	M. Eapen (Milwaukee)
14.50-15.10	Increasing use of hematopoietic stem cell transplantation for ethnic minorities	M. Oudshoorn (Leiden)
15.10-15.30	Role of non HLA markers for donor selection	R. Tamouza (Paris)
15.30-15.50	Criteria of donor choice for cord blood transplantation	A. Ruggeri (Paris)
15.50-16.30	Discussion	
16.30-17.00	<i>Coffee break</i>	

SESSION V: CORD BLOOD BANKING

17.00-18.30 Chair: E. Baudoux (Liège)

17.00-17.15	State of the art	E. Baudoux (Liège)
Discussants:		
17.15-17.30	Assessment of parameters affecting the quality of cord blood units	G. Koegler (Düsseldorf)
17.30-17.45	Updating the cord blood unit inventory to meet current needs	S. Querol (Barcelona)
17.45-18.00	Improving outcomes of cord blood transplantation by screening potency of cord blood units before release from the cord blood bank	J. Kurtzberg (Durham)
18.00-18.10	Eurocord registry, a real support for cord blood bank's accreditation	I. Ionescu (Agence de la biomédecine - La Plaine Saint Denis)
18.10-18.25	Role of registries to analyze outcomes data - Eurocord - Netcord	V. Rocha (Oxford)

Saturday 26th October, 2013

SESSION VI: INTERNATIONAL OBSERVATORY ON SICKLE CELL DISEASE

8.30-13.45 Chair: E. Gluckman (Centre Scientifique de Monaco CSM and Paris)

8.30-8.50	Sickle cell disease global perspective	E. Gluckman (Paris)
Discussants:		
8.50-9.10	Hydroxycarbamide in the treatment of sickle cell disease	M. de Montalembert (Paris)
9.10-9.30	Is sickle cell disease an autonomic nervous system disorder: what triggers the transition from steady state to crisis?	T. Coates (Los Angeles)
9.30-9.50	Sickle cell disease: genetic etiologies for phenotypic diversity	J. Elion (Paris)
9.50-10.10	Registry of pregnant women with sickle cell disease	M. Cavazzana (Paris)
10.10-10.45	<i>Coffee break</i>	
10.45-11.00	Hematopoietic stem cell transplant for sickle cell disease	F. Bernaudin (Paris)
11.00-11.20	Haplo-identical related hematopoietic stem cell transplant for sickle cell disease	R. Jones (Baltimore)
11.20-11.40	New directions in allogeneic stem and cellular therapy in patients with sickle cell disease	M. Cairo (New York)

Programme 02/10/2013

11.40-12.00	Nicord expanded hematopoietic progenitor cells bridge hematopoiesis and facilitate engraftment after myeloablative chemotherapy for patients sickle cell disease	J. Kurtzberg (Durham)
12.00-12.20	Hematopoietic stem cell transplant for sickle cell disease in Brazil	B. Simoes (Ribeirao Preto)
12.20-12.35	Haemoglobinopathies and malaria in Africa	D. Diallo (Bamako)
12.35-13.05	Epidemiology and treatment of sickle cell in Senegal including hydroxycarbamide, transfusions and chelation	
12.35-12.50	in children	I. Diagne (Saint Louis - Senegal)
12.50-13.05	in adults	S. Diop (Dakar)
13.05-13.15	Long term outcome of paediatric patients undergoing haploidentical and matched related haematopoietic cell transplantation for sickle cell disease	M. Dallas (Memphis)
13.15-13.45	Discussion	
13.45-14.30	<i>Lunch and poster viewing</i>	

SESSION VII: HOW TO IMPROVE OUTCOME OF UNRELATED CORD BLOOD TRANSPLANT

14.30-18.15 Chair: J. Wagner

Discussants:

14.30-15.00	State of the art	J. Wagner (Minneapolis)
15.00-15.20	Optimization of cord blood transplant for hematologic malignancies: graft, conditioning, graft versus host disease.	J. Barker (New York)
15.20-15.40	Results of single and double cord blood in adult malignancies: cost efficiency study	A. Ruggeri (Paris)
15.40-16.15	<i>Coffee break</i>	
16.15-16.35	Conditioning for cord blood transplant	G. Sanz (Valencia)
16.35-16.55	Cord blood transplant in children with non malignant disease	E. Gluckman (Paris)
16.55-17.15	Cord blood transplantation for adults: what have we learned	D. Weisdorf (Minneapolis)
17.15-18.15	Selected abstract presentations	
17.15-17.22	Unrelated donor umbilical cord blood transplantation (UCBT) for hemoglobinopathy using reduced intensity conditioning (RIC)	A. Abraham (Washington)
17.22-17.29	Outcome analysis of unrelated cord blood transplantation in Korea	Y.H. Lee (Seoul)
17.29-17.36	Reduced intensity conditioning regimen combined with single unit cord blood transplantation is effective and safe for children with inherited metabolic disorders and combined immunodeficiency diseases	P. Szabolcs (Pittsburgh)
17.36-17.43	Long term survival in 365 pediatric recipients of unrelated cord blood transplantation (UCBT) with a single 4/6 matched cord blood unit after myeloablative therapy: Impact of HLA and race/ethnicity	V. Prasad (Durham)
17.43-17.50	Allogeneic hematopoietic stem cell transplantation (HSCT) for treatment of high risk hemoglobinopathy patients lacking a fully HLA-matched sibling donor using a novel myeloablative, reduced toxicity conditioning regimen	S. Kharbanda (Palo Alto)

18.15-19.15 **SATELLITE SYMPOSIUM ROOM C**
Sergio Querol

Using Automation for the Safe Preparation of Cells for Cryopreparation

This is a symposium organized and funded by Biosafe SA

Sunday 27th October, 2013

SESSION VIII: COMPARISON OF CORD BLOOD TRANSPLANTS WITH OTHER SOURCES OF STEM CELLS

9.00-12.30 Chair: V. Rocha

Discussants

9.00-9.15	Haplo versus cord blood: pros cord blood	J. Wagner (Minneapolis)
9.15-9.30	Haplo versus cord blood: pros Haplo	R. Jones (Baltimore)
9.30-9.50	Comparison of cord blood transplants with other sources of stem cells	V. Rocha (Oxford)
9.50-10.10	Algohythm of donor choice	K. Ballen (Boston)

10.10-10.30 *Coffee break*

10.30-11.10	The RTN Policy: a comprehensive algohythm of the allogeneic hematopoietic stem cell transplant for adults with hematological malignancies	W. Arcese (Rome)
11.10-11.30	Comparison between related haploidentical transplants in children	F. Locatelli (Rome)

11.30-12.30 **Round table: summary and future directions**

Chairs : H.E. Broxmeyer, E.J. Shpall, E. Petersdorf, E. Baudoux, E. Gluckman, V. Rocha

End of meeting

SATELLITE WORKSHOP ON SICKLE CELL DISEASE IN EMERGING COUNTRIES : 14:00 - 17:30

Sessions will be in French and English with simultaneous translation

SESSION I: SICKLE CELL DISEASE IN EMERGING COUNTRIES
LA DREPANOCYTOSE DANS LES PAYS EMERGENTS

14.00-15.00 **Chairs: Belinda Simoes (Ribeirao Preto), Jacques Elion (Paris – Guadeloupe)**

Discussants:

14.00-14.15	Sickle cell disease in India	La drépanocytose en Inde	D. Jain (Nagpur)
14.15-14.30	Networks, research tools and cooperation: the example of network research on sickle cell disease in Central Africa	Les réseaux, outils de recherche et de coopération : exemple du réseau de recherche sur la drépanocytose en Afrique centrale	L. Tshilolo (Kinshasa)
14.30-14.45	Treatment with hydroxycarbamide, transfusion and iron chelation: issues specific to Africa	Le traitement par hydroxycarbamide, la transfusion et la chélation du fer: des problèmes spécifiques à l'Afrique	J. Makani (Dar-es-Salaam)
14.45-15.00	Problems related to the availability of opioids in Africa	Problèmes liés à la disponibilité des morphiniques en Afrique	E. Kafando (Ouagadougou)

15.00-15.20 *Coffee Break*

SESSION II: PAROLE AUX ASSOCIATIONS / WORDS FROM THE FAMILY SUPPORT GROUPS

15.20-17.30 Chairs: Dipty Jain (Nagpur), Danielle Léna (Marseille)

Discussants:

15.20-15.25	Introduction : Santé Sud	Introduction : Santé Sud	N. Hanssen (Marseille)
15:25-15.37	Association for the struggle against sickle cell disease in Niger	Association de Lutte contre la drépanocytose du Niger	F. Hima (Niamey)
15:37-15.49	Struggle against sickle cell disease Madagascar-France	Lutte contre la Drépanocytose Madagascar-France	P. Jeannot (Chatillon)
15:49-16.01	Sickle Cell Foundation of Ghana	La fondation de la Drépanocytose du Ghana	P. Mensah (Kumasi)
16.01-16.13	Support association for SCD in Mauritania	Association de Soutien aux Drépanocytaires en Mauritanie	M. Wane (Nouakchott)
16.13-16.25	Senegalese Association for the struggle against Sickle Cell Disease	Association Sénégalaise de Lutte contre la Drépanocytose	M. Ndiaye (Dakar)
16.25-16.37	Sickle Cell Society (Royaume Uni)	Sickle Cell Society (United Kingdom)	J. James (London)

16.37-17.30 GENERAL DISCUSSION

Chairs: Julie Makani (Dar-es-Salaam), Léon Tshilolo (Kinshasa)